NOVARTIND vs SUDEEPPHRM: Stock Comparison
Sudeep Pharma Ltd is the larger company by market capitalisation. Novartis India Limited shows a lower P/E, a higher dividend yield and faster revenue growth, while Sudeep Pharma Ltd shows a higher ROE, a higher ROCE and a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
NOVARTIND leads 6; SUDEEPPHRM leads 7 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | NOVARTIND | SUDEEPPHRM |
|---|---|---|
| Sector | Healthcare | — |
| Industry | Pharmaceuticals | — |
Price
| Metric | NOVARTIND | SUDEEPPHRM |
|---|---|---|
| Live Price | ₹1,486.3 | ₹1,127.2 |
| Day Change | -1.06% | -0.35% |
| Volume | 6,845 | 1.5 L |
| 52-Week High | ₹1,780 | ₹1,180 |
| 52-Week Low | ₹950 | ₹524.05 |
| Distance from 52W High | -16.5% | -4.47% |
Valuation
| Metric | NOVARTIND | SUDEEPPHRM |
|---|---|---|
| Market Cap | ₹3,664 Cr | ₹12,743 Cr |
| P/E Ratio | 37.65x | 69.8x |
| P/B Ratio | 4.5x | 14.45x |
| EPS | ₹37.76 | ₹16.8 |
| Book Value | ₹331.34 | ₹78.2 |
| Dividend Yield | 1.7% | 0.14% |
Growth
| Metric | NOVARTIND | SUDEEPPHRM |
|---|---|---|
| Revenue Growth (TTM YoY) | 8% | 0% |
| EPS Growth (TTM YoY) | -13.8% | 0% |
| Qtr Sales Growth | 7.95% | 26.7% |
| Qtr Profit Growth | -13.8% | 31.6% |
Profitability & Leverage
| Metric | NOVARTIND | SUDEEPPHRM |
|---|---|---|
| ROE | 11.6% | 25.2% |
| ROCE | 16.2% | 28.2% |
| Net Margin | 26.3% | 27.14% |
| Operating Margin | 26.6% | 34.5% |
| Debt to Equity | 0x | 0.17x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | NOVARTIND | SUDEEPPHRM |
|---|---|---|
| Promoter Holding | 0% | 76.15% |
| FII Holding | 0.16%▼ 0.01 pp | 1.81%▲ 0.26 pp |
| DII Holding | 1.36%▲ 0.83 pp | 15.65%▼ 2.46 pp |
| Public Holding | 27.8%▼ 0.81 pp | 6.39%▲ 2.21 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Novartis India Limited and Sudeep Pharma Ltd.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.